FibroGen Inc. (FGEN)

NASDAQ: FGEN · Real-Time Price · USD

0.34

0.00 (0.59%)

At close: May 01, 2025, 3:59 PM

0.34

0.80%

After-hours: May 01, 2025, 04:17 PM EDT

0.59% (1D)

Bid	0.34
Market Cap	34.08M
Revenue (ttm)	29.62M
Net Income (ttm)	-47.58M
EPS (ttm)	-1.53
PE Ratio (ttm)	-0.22
Forward PE	-0.43
Analyst	Buy

Ask	0.35
Volume	574,672
Avg. Volume (20D)	3,351,557
Open	0.34
Previous Close	0.34
Day's Range	0.34 - 0.35
52-Week Range	0.18 - 1.74
Beta	0.88

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 14, 2014

Employees 225

Stock Exchange NASDAQ

Ticker Symbol FGEN

Website https://www.fibrogen.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for FGEN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 2864.72% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-21.8%

FibroGen shares are trading lower. The company rep... Unlock content with Pro Subscription

2 months ago

+37.44%

FibroGen shares are trading higher after the company announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

News

1 month ago · seekingalpha.com

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call P...

2 months ago · benzinga.com

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.

2 months ago · reuters.com

FibroGen sells China unit to AstraZeneca in deal worth $160 million

FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million.